Gadobenic acid
- Generic Name
- Gadobenic acid
- Brand Names
- Multihance
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28GdN3O11
- CAS Number
- 113662-23-0
- Unique Ingredient Identifier
- 15G12L5X8K
- Background
Gadobenic acid (in the form of gadobenate dimeglumine) is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding leads to an increased relaxivity of gadobenate dimeglumine and, consequently, to a considerably increased signal intensity over that of other agents.
- Indication
Gadobenate dimeglumine is indicated for use in magnetic resonance imaging (MRI) of the central nervous system in adult and pediatric patients in order to visualize lesions with abnormal blood-brain barrier or abnormal vascularity of the brain, spine, and associated tissues. It is also indicated for use in magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease.
- Associated Conditions
- Vascular Occlusion
- Associated Therapies
- -
Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
- Conditions
- Congenital Heart Disease
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 160
- Registration Number
- NCT06406517
- Locations
- 🇺🇸
University of California San Diego Health, San Diego, California, United States
Comparison of Contrast Agents in Liver MR for the Detection of Hepatic Metastases
- Conditions
- Oligometastatic DiseaseLiver MetastasesColorectal Cancer
- Interventions
- First Posted Date
- 2021-07-22
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 55
- Registration Number
- NCT04973007
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
- Conditions
- Prostate Carcinoma
- Interventions
- Drug: Fluorine F 18 DCFPyLDrug: Gadobenate DimeglumineDrug: GadobutrolProcedure: Magnetic Resonance ImagingProcedure: Multiparametric Magnetic Resonance ImagingProcedure: Positron Emission TomographyProcedure: Transrectal Ultrasonography Guided Biopsy
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 106
- Registration Number
- NCT04910425
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Conditions
- Motor FunctionCognitive FunctionContrast Media
- Interventions
- Procedure: Motor TestsProcedure: Cognitive TestsProcedure: Unenhanced-MRI of the brainProcedure: Gadolinium MeasurementsDrug: Gadoterate meglumineDrug: Gadoxetate disodiumDrug: Gadobenate dimeglumineDrug: GadobutrolDrug: GadodiamideDrug: Gadoteridol
- First Posted Date
- 2020-05-04
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 2076
- Registration Number
- NCT04373564
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇧🇷Hospital Santa Marta, Taguatinga, Distrito Federal, Brazil
Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions
- Conditions
- Brain NeoplasmRecurrent Malignant Brain NeoplasmLymphomaMetastatic Malignant Neoplasm in the Brain
- Interventions
- First Posted Date
- 2019-10-21
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT04132843
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
- Conditions
- Breast CancerDuctal Carcinoma in Situ - Category
- Interventions
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 13
- Registration Number
- NCT03703492
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
- Conditions
- Central Nervous System DiseasesCentral Nervous System Neoplasms
- Interventions
- First Posted Date
- 2017-05-10
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Bracco Diagnostics, Inc
- Target Recruit Count
- 352
- Registration Number
- NCT03147989
- Locations
- 🇺🇸
Sarasota Memorial Hospital, Sarasota, Florida, United States
QSM and Regional DCE MRI Permeability Using GOCART Technique
- Conditions
- Intracranial Neoplasm
- Interventions
- Device: Dynamic Contrast-Enhanced Magnetic Resonance ImagingDrug: Gadobenate DimeglumineDrug: Gadoterate MeglumineDevice: Magnetic Resonance Imaging
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT03091803
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases
- Conditions
- Adult Anaplastic (Malignant) MeningiomaAdult Anaplastic OligodendrogliomaAdult Brain Stem GliomaAdult Choroid Plexus NeoplasmAdult Diffuse AstrocytomaAdult EpendymoblastomaAdult EpendymomaAdult Giant Cell GlioblastomaAdult GlioblastomaAdult Gliosarcoma
- Interventions
- Procedure: Dynamic Contrast-Enhanced Magnetic Resonance ImagingDrug: Gadobenate DimeglumineDrug: GadobutrolRadiation: Gadopentetate Dimeglumine
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 14
- Registration Number
- NCT02967380
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
- Conditions
- CNS LesionBlood Brain Barrier Defect
- Interventions
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Guerbet
- Target Recruit Count
- 312
- Registration Number
- NCT02633501
- Locations
- 🇮🇹
Ospedali Riuniti di Ancona, Ancona, Italy
🇮🇹AO S. Andrea Universita La Sapienza, Roma, Italy
🇭🇺Pecsi Tudomany Egyetem Klinikai kozpont Idegsebeszeti Klinica, Pécs, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.